Drug intelligence / Profile preview

MDX-012

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**MDX-012** is a fully human monoclonal antibody targeting interleukin-8 (IL-8), a key chemokine that promotes inflammation by attracting neutrophils and other immune cells. Developed by Medarex (now part of Bristol Myers Squibb), it inhibits IL-8-mediated signaling to reduce tumor growth and inflammatory responses. It has been investigated primarily for oncology applications, including glioblastoma, and inflammatory conditions such as palmoplantar pustulosis and chronic obstructive pulmonary disease (COPD), with potential extension to autoimmune diseases.

Targets

IL8 (C-X-C Motif Chemokine Ligand 8)

Beyond the preview

Go deeper on MDX-012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDX-012.

Explore the full profile